Pemphigus in elderly adults: Clinical presentation, treatment, and prognosis

Journal of the American Geriatrics Society

Volumn 60, Issue 6, 2012, Pages 1185-1187

  Ingen Housz Oro, Saskia ^a   Alexandre, Marina ^b   Le Roux Villet, Christelle ^b   Picard Dahan, Catherine ^c   Tancrède Bohin, Emmanuelle ^d   Wallet Faber, Nadège ^e   Mahé, Emmanuel ^f   Begon, Edouard ^g   Francès, Camille ^h   Sigal, Michèle ⁱ   Grootenboer Mignot, Sabine ^c   Aucouturier, Françoise ^d   André, Chantal ^a   Wolkenstein, Pierre ^a   Chosidow, Olivier ^a   Prost Squarcioni, Catherine ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e Institut Cochin   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g CENTRE HOSPITALIER RENÉ DUBOS   (France)

^h HÔPITAL TENON   (France)

ⁱ CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; DAPSONE; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

AGED; BULLOUS PEMPHIGOID; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; ELDERLY CARE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFECTION; LETTER; MALE; MYOPATHY; ONSET AGE; OUTCOME ASSESSMENT; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; DAPSONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLIC ACID ANTAGONISTS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; PEMPHIGUS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEROIDS; TREATMENT OUTCOME;

EID: 84862233366     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2012.03987.x     Document Type: Letter

References (10)

1. Herrero-González JE, Iranzo P, Benítez D et al. Correlation of immunological profile with phenotype and disease outcome in pemphigus. Acta Derm Venereol 2010;90:401-405.
2. Tallab T, Joharji H, Bahamdan K et al. The incidence of pemphigus in the southern region of Saudi Arabia. Int J Dermatol 2001;40:570-572. (Pubitemid 33081043)
3. Chams-Davatchi C, Valikhani M, Daneshpazhooh M et al. Pemphigus: Analysis of 1209 cases. Int J Dermatol 2005;44:470-476. (Pubitemid 40867550)
4. Harman KE, Albert S, Black MM et al. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-937. (Pubitemid 37541976)
5. Chams-Davatchi C, Esmaili N, Daneshpazhooh M et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007;57:622-628. (Pubitemid 47384928)
6. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-552. (Pubitemid 47236279)
7. Langan SM, Smeeth L, Hubbard R et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: Population based cohort study. BMJ 2008;337:a180.
8. Harman KE, Seed PT, Gratian MJ et al. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001;144:775-780. (Pubitemid 32374780)
9. Murrell DF, Dick S, Ahmed AR et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043-1046.
10. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007;211:144-156. (Pubitemid 46195513)